BioMarin (BMRN) Q4 2025 Earnings Transcript

BioMarin reported 2025 revenue of $3.22 billion, up 13%, with Voxzogo revenue rising 26% to $927 million and operating cash flow increasing 45% to $828 million. Management guided 2026 revenue to $3.325 billion-$3.425 billion and non-GAAP EPS to $4.95-$5.15, while warning that lower KUVAN/Roctavian royalties, one-time Q4 order timing, and Amicus integration costs will weigh on near-term results. The company also highlighted pipeline progress and acquisitions, but Q1 is expected to be the weakest quarter of 2026 and Amicus guidance will be added only after close.

Analysis

BMRN’s setup is better than the headline guidance implies because the business is transitioning from a single-growth-asset story to a platform with multiple shots on goal: base enzyme cash flows, Voxzogo duration, and acquisition-driven expansion. The key second-order effect is that the company is using a period of unusually strong operating leverage to fund optionality while still holding organic margins near 40%; that de-risks the equity versus typical mid-cap biotech names where pipeline investment competes with profitability. The market may still underappreciate how much the international footprint matters — once a product reaches global scale, reimbursement renegotiations can actually widen patient access and offset nominal pricing pressure.

The near-term risk is not demand collapse but quarterly noise: Q1 looks mechanically weak, and management is explicitly warning that revenue will be back-half loaded again. That creates a likely setup where the stock can lag into the first half if investors focus on sequential deceleration, then re-rate on the back of hypochondroplasia data, Palynziq’s adolescent label decision, and BMN 351 readouts. The more meaningful downside is competitive: if the new achondroplasia entrants are cleaner on convenience and perceived switching friction proves lower than management expects, Voxzogo’s growth curve could flatten faster than the guide suggests, especially in markets with lower historical penetration and higher physician sensitivity to route-of-administration.

The contrarian read is that the market may be over-fixated on the upcoming competition and underpricing the incumbency advantage created by long-duration safety data in pediatrics. In diseases where doctors are treating infants, evidentiary depth and caregiver trust matter more than convenience than in adult chronic therapies; that gives BMRN a defensible moat even if an oral competitor is easier to administer. The bigger upside surprise would be an earlier-than-expected lift from acquisition synergies plus expanded diagnosis in Fabry/Pompe, which would show up as faster-than-modeled top-line acceleration in 2027 rather than immediate 2026 earnings.

Key Decisions for Investors

• Long BMRN common into Q1 weakness, with a 6-12 month horizon; use any post-earnings or post-close pullback to build, targeting a re-rating on 2H data/regulatory catalysts. Risk: if Voxzogo switching proves more elastic than management assumes, the stock could de-rate on 2027 growth concerns.
• Buy BMRN Jan-2027 calls or call spreads to express the view that 2026 is a bridge year and the real upside comes from hypochondroplasia, BMN 401, and Amicus integration; structure for limited downside because Q1/EPS seasonality will keep the tape noisy.
• Pair trade: long BMRN / short a higher-valuation orphan-drug peer with less pipeline depth and more single-product exposure; thesis is that BMRN’s cash generation and pipeline breadth are being undercompensated versus peers relying on one catalyst.
• Watch for a short-term selloff around Q1 numbers or if achondroplasia competition headlines intensify; if the stock gaps lower on seasonal weakness without a change in full-year guidance, add exposure rather than chase strength.
• Avoid shorting BMRN outright unless data on switching materially worsens; the risk/reward is poor because multiple 2026 catalysts can re-anchor estimates quickly, while downside from Q1 timing is likely temporary.